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Skeletal and smooth muscle can mutually transdifferentiate, but
little molecular insight exists as to how each muscle program may
be subverted to the other. The myogenic basic helix–loop–helix
transcription factors MyoD and myogenin (Myog) direct the de-
velopment of skeletal muscle and are thought to be dominant over
the program of smooth muscle cell (SMC) differentiation. Myocar-
din (Myocd) is a serum response factor (SRF) coactivator that
promotes SMC differentiation through transcriptional stimulation
of SRF-dependent smooth muscle genes. Here we show by lineage-
tracing studies that Myocd is expressed transiently in skeletal
muscle progenitor cells of the somite, and a majority of skeletal
muscle is derived from Myocd-expressing cell lineages. However,
rather than activating skeletal muscle-specific gene expression,
Myocd functions as a transcriptional repressor of Myog, inhibiting
skeletal muscle differentiation while activating SMC-specific
genes. This repressor function of Myocd is complex, involving
histone deacetylase 5 silencing of the Myog promoter and Myocd’s
physical contact with MyoD, which undermines MyoD DNA binding
and transcriptional synergy with MEF2. These results reveal a
previously unrecognized role for Myocd in repressing the skeletal
muscle differentiation program and suggest that this transcrip-
tional coregulator acts as a bifunctional molecular switch for the
smooth versus skeletal muscle phenotypes.
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Skeletal muscle identity is controlled primarily by four skeletalmuscle-specific myogenic regulatory factors (MRFs), MyoD,
myogenin (Myog), Myf5, and MRF4, which cooperate with the
myocyte enhancer factor-2 (MEF2) transcription factor to acti-
vate skeletal muscle gene expression (1). Although the MRFs act
in a dominant manner and can convert a variety of cell types,
including smooth muscle, into skeletal muscle (2), there are
settings in which skeletal muscle can be induced to transdiffer-
entiate into other cell types, suggesting that the MRFs may be
subordinate to other cell-specific transcription factors (3, 4).
Much of the work related to transcriptional regulation of
smooth muscle cell (SMC) differentiation has focused on serum
response factor (SRF), a widely expressed transcription factor
that binds the CArG box found in the regulatory regions of many
SMC-specific genes (5). Genetic inactivation of SRF (6) and
CArG mutagenesis studies in transgenic mice (7) have con-
firmed the necessity of CArG-SRF in controlling SMC differ-
entiation. However, SRF is only a weak transcriptional activator
and requires interacting cofactors that recruit proteins to pro-
mote a permissive state for gene transcription. One such cofactor
is myocardin (Myocd), which is expressed primarily in cardiac
and SMCs and displays high transcriptional activity (8). Myocd
can activate SMC-specific genes (9), and genetic deletion of
Myocd in mice leads to defective vascular SMC differentiation
(10). Thus, Myocd displays features of a master regulator of the
SMC phenotype.
In an effort to define the cells of the cardiovascular system
derived from Myocd-dependent lineages, we performed lineage
tracing in mouse embryos by introducing Cre recombinase into
the Myocd locus and monitoring the expression of a Cre-
dependent lacZ from the ROSA26 reporter (R26R) mouse line.
Consistent with previous expression data, cardiac and vascular
SMCs are derived from Myocd-dependent lineages. Surprisingly,
skeletal muscle in these mice also expressed lacZ, indicating its
derivation from a Myocd-dependent lineage. However, rather
than functioning as an activator of skeletal muscle gene expres-
sion, Myocd represses MyoD-mediated stimulation of the Myog
promoter and blocks skeletal muscle differentiation in vitro. At
the same time, Myocd transactivates SMC contractile protein
genes, thereby converting skeletal myoblasts to an SMC pheno-
type. These results suggest that Myocd acts as a bifunctional
switch for muscle differentiation by concurrently opposing the
gene program for skeletal muscle differentiation and specifying
a SMC fate.
Results
Myocd Is Expressed in Progenitors of Skeletal Muscle. Myocd is
expressed throughout the atrial and ventricular myocardium and
in a subset of vascular and visceral SMCs (8). To trace the
embryonic origins of Myocd-expressing lineages, we performed
lineage tracing by creating a mouse in which the first exon of
Myocd was replaced with a Cre-recombinase cassette [support-
ing information (SI) Fig. 7]. Hemizygous Myocd-Cre knockin
mice were crossed into the R26R mouse line, allowing for
persistent activation of lacZ expression after Cre-mediated
excision. As expected from prior in situ hybridization studies of
Myocd expression (8), we observed lacZ staining in the devel-
oping heart, dorsal aorta, and head mesenchyme during early
development (Fig. 1). LacZ expression was first seen in cardi-
omyocytes of the cardiac crescent at embryonic day 7.5 (E7.5)
and subsequently in the linear heart tube and in all chambers of
the heart (Figs. 1 and 2). We also noted expression of lacZ in
SMCs of the embryonic and adult aorta and other vascular
structures such as renal arterioles (Fig. 2).
Unexpectedly, lacZ-positive cells were observed in the somites
of mouse embryos beginning at E8.5 and throughout mature
skeletal muscle fibers at later stages (Figs. 1 and 2). Histological
sections of an E9.0 embryo further confirmed lacZ-stained
skeletal progenitors within the dermamyotome of the somites,
the origin of epaxial and hypaxial skeletal muscle (Fig. 2 C and
D). Expression also was observed in a subset of sclerotome cells.
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These lineage-tracing studies suggest that Myocd specifically
marks cardiac, smooth, and skeletal muscle lineages during
embryonic development.
Myocd Inhibits the Skeletal Muscle Program of Differentiation. We
tested whether Myocd was dominant or subordinate to the
skeletal muscle gene program by transducing C2C12 and BC3H1
skeletal muscle cell lines with a Myocd- or lacZ-expressing
adenovirus and assaying for expression of smooth and skeletal
muscle genes. All Myocd expression studies were done with the
short form of Myocd lacking the N-terminal extension shown
recently to interact with MEF2 (11). As shown in Fig. 3A, ectopic
Myocd expression elicited a dramatic decrease in Myog mRNA
while elevating expression of two highly specific SMC markers,
smooth muscle calponin and smooth muscle myosin heavy chain
(Myh11) (12, 13). Decreases in other skeletal muscle markers
(e.g., myf5, MyoD) also were observed with Myocd overexpres-
sion (data not shown). Western blotting revealed comparable
changes in skeletal and SMC proteins in response to Myocd
expression (Fig. 3B). Immunostaining further demonstrated a
loss in Myog and elevations in Myh11 with Myocd overexpres-
sion (SI Fig. 8 A and B). To verify and extend these findings, we
generated several independent clones of C2C12 cells stably
transfected with Myocd. Western blotting of such cells showed
uniform decreases in Myog and sarcomeric myosin and an
Fig. 1. Tracing Myocd-expressing cell lineages during mouse embryogenesis. Myocd gene expression activity was studied in embryos from Myocd-Cre  R26R
crosses. LacZ-positive cells are observed in the cardiac crescent at E7.5, in the linear heart tube at E8.0, and throughout the entire heart at E8.5–E9.0 and thereafter,
as well as in head mesenchyme. Note the strong staining in rostral somites beginning at E8.5 and continuing in a rostral-caudal gradient at E9.0. At E13.0, much
of the embryo’s skeletal muscle was stained positive for lacZ expression. (Inset) Skeletal muscle staining in distal limb. Red lines labeled A–C in the E9.0 embryo
mark the respective levels of transverse sections in Fig. 2 A–C.
Fig. 2. Histology of Myocd-Cre  R26R mice. Sections from Myocd-Cre 
R26R E9.0 embryos (A–D) or adults (E–G) were stained for lacZ expression,
sectioned, and counterstained with nuclear fast red. (A) LacZ-positive cells in
the head mesenchyme (hm) between the forebrain (fb) and hindbrain (hb). (B)
LacZ expression in cells of the left ventricle (v), outflow tract (oft), and
mesenchymal cells (m) ventral of the neural tube (nt). (C) LacZ expression in
cells of the somites (so) and dorsal aorta (da). (D) LacZ expression in der-
mamyotome and sclerotome. (E) LacZ expression in SMCs of adult aorta. (F)
LacZ expression in SMCs of a kidney arteriole. (G) LacZ expression in adult limb
skeletal muscle.
Fig. 3. Myocd represses skeletal myogenesis. (A) RT-PCR analysis of Myog
and two smooth muscle markers (smooth muscle calponin, Cnn1, and Myh11)
in BC3H1 cells and C2C12 cells induced to differentiate 3 days after adenoviral
transduction with LacZ or Myocd. (B) Western blot of indicated markers in
C2C12 cells treated as in A. (C) Immunofluorescence staining (red) of Myog (a
and d) or sarcomeric myosin (b and e) in C2C12 cell lines stably transfected with
empty vector (a and b) or Myocd (d and e). Phase-contrast images of C2C12 cells
stably transfected with empty vector (c) or Myocd ( f) and cultured in differ-
entiation medium for 3 days. (Magnification: a, b, d, and e, 400; c and f,
200.) (D) RT-PCR of indicated genes in PAC1 cells transduced 3 days with
either LacZ or Myocd at the indicated MOI. (E) Quantitative RT-PCR of Myocd
and Myog in PAC1 cells transfected 3 days with siRNA to either Myocd or a
control scrambled sequence. Normalized data expressed relative to scrambled
siRNA (set to 1). *, P  0.01; **, P  0.05. Data are representative of two
independent experiments.














increase in Myh11 expression (SI Fig. 8C). These results were
confirmed by immunostaining (Fig. 3C). All stable clones ex-
pressing Myocd were unable to differentiate into myotubes (Fig.
3Cf and SI Fig. 8D).
We considered the possibility that diminishing myocardin
levels in cultured SMCs might render them susceptible to
transdifferentiation to a more skeletal muscle fate through
up-regulation of Myog. Indeed, overexpression of Myocd in
PAC1 cells, which display features of both smooth and skeletal
muscle (14), stimulated Myh11 and attenuated Myog expression
(Fig. 3D), whereas siRNA knockdown of Myocd augmented
expression of Myog mRNA (Fig. 3E). We conclude that Myocd
is a repressor of skeletal muscle differentiation in vitro.
Myocd Represses MyoD-Dependent Activation of the Myog Promoter.
To determine whether Myocd repressed Myog expression at the
transcriptional level, we evaluated effects of Myocd on activation
of the Myog promoter, which contains MyoD-binding E-box
elements and an MEF2 site (15). Both MEF2- and MyoD-
dependent activation of the Myog promoter were reduced in the
presence of Myocd (Fig. 4A Left), and such repression was
dose-dependent (Fig. 4B). Myocd could repress the Myog pro-
moter irrespective of point mutations in each myogenic factor
regulatory element, as well as a conserved upstream CArG box
(SI Fig. 9). Myocd had no effect on MEF2-dependent stimula-
tion of the histidine-rich calcium-binding protein promoter (Fig.
4A Center) (16) and activated a synthetic MEF2-dependent
reporter (Fig. 4A Right), suggesting the block in Myog promoter
activation is not a consequence of generalized transcriptional
squelching or an inhibition in MEF2 DNA binding. In contrast
to MEF2, when a tethered MyoD–E47 dimer (17) was used as the
myogenic activator, Myocd repressed all three promoters (Fig.
4A). Remarkably, MyoD had a minimal effect on Myocd’s ability
to activate several SMC-specific promoters (Fig. 4C). Collec-
tively, these results indicate that Myocd transcriptionally re-
presses MyoD-mediated Myog promoter activity in a CArG/
SRF-independent manner, whereas MyoD is ineffective in
blocking Myocd transactivation of SMC promoters.
Multiple Domains in Myocd Are Necessary for Repression of the Myog
Promoter. Alternate and mutant forms of Myocd were tested for
transcriptional repression of the Myog promoter. The long form
of Myocd (amino acids 1–935), shown previously to interact with
MEF2 (11), inhibited Myog promoter activation by 80% (Fig.
4D). Two shorter forms of Myocd (amino acids 128–935 and
79–935) were 5–10 times more potent in repression, suggesting
Fig. 4. Myocd represses the Myog promoter. (A) C2C12 myoblasts were
cotransfected with the indicated luciferase reporters and myogenic activators
in the absence (open bars) or presence (filled bars) of Myocd. Luciferase
activity is expressed as normalized fold increase above baseline (no myogenic
activators) set to 1. (B) C2C12 myoblasts cotransfected with 660 Myog
promoter-luciferase (Myog-Luc) and MyoD-E47MEF2C in absence or pres-
ence of increasing concentrations of Myocd. Luciferase activity is expressed as
a percentage of control set to 100. (C) PAC1 cells cotransfected with the
indicated SMC promoters linked to luciferase in absence or presence of
Myocd  MyoD. Luciferase activity is expressed as normalized fold increase to
each luciferase reporter alone (set to 1). The Myog promoter is shown as a
positive control for MyoD activation. (D) C2C12 myoblasts cotransfected with
Myog-Luc and MyoD-E47MEF2C in the presence of pcDNA control vector or
each indicated Myocd expression plasmid (expression validated by Western
blotting) (data not shown). The domains of the Myocd expression plasmids are
indicated with colored boxes labeled as N-terminal domain (NTD), basic (),
poly glutamine (Q), SAP (S), leucine zipper (LZ), and TAD. The numbers at right
reflect the percentage normalized luciferase activity for each Myocd construct
relative to the pcDNA control vector alone (set to 100). All data are represen-
tative of two independent experiments.
Fig. 5. Myocd interferes with MEF2–MyoD association and MyoD DNA
binding. (A) 10T1/2 cells were cotransfected with UAS-Luciferase reporter and
GAL4-MEF2C  MyoD-E47 in the absence (open bars) or presence (filled bars)
of Myocd. Luciferase activity is expressed as a percentage of the control (first
bar set to 1). (B) Gel-shift assay with radiolabeled E1-box of Myog promoter
incubated with in vitro translated Myc-MyoD, MyoD’s dimerization partner,
E12  Myocd. The MyoD–E12 nucleoprotein complex is reduced in the pres-
ence of in vitro-translated Myocd and is supershifted with an Myc antibody. (C)
Gel-shift assay by using an oligonucleotide corresponding to the E-box in the
MCK promoter incubated with nuclear extracts from 10T1/2 cells cotrans-
fected with the tethered MyoD-E47 expression plasmid  Myocd. Note atten-
uated MyoD–E47 complex in the presence of Myocd. (D) (Left) GST pulldown
assay shows Myocd interacting with in vitro translated MyoD. (Center and
Right) Validation of the presence of each protein by autoradiography and
Coomassie blue staining, respectively. (E) C2C12 myoblasts transfected with
FLAG-tagged Myocd and then immunoprecipitated with a Flag antibody,
followed by immunoblotting as indicated. Results are representative of two
independent studies.
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the extended N terminus partially masks full repressive activity.
The leucine zipper and basic domains of Myocd were dispensable
for promoter inhibition, implying that Myocd repression is
independent of its oligomerization or association with SRF,
respectively. However, the C-terminal transactivation domain
(TAD) and, to a lesser degree, the poly Q and SAP domains were
necessary for full repression of the Myog promoter (Fig. 4D).
These results suggest that multiple domains of Myocd participate
in the repression of the Myog promoter.
Myocd Blunts MEF2–MyoD Functional Association and MyoD DNA
Binding. To address whether Myocd interfered with the func-
tional association between MEF2 and MyoD, we used the GAL4
two- and three-hybrid luciferase assay. As shown in Fig. 5A,
Myocd had little effect on GAL4-MEF2-directed reporter ac-
tivity, but reduced the additive effects of MyoD-E47. Myocd also
could repress GAL4-MyoD activity (SI Fig. 10A). Gel-shift
assays revealed that Myocd attenuated the binding of in vitro
translated MyoD and its dimerization partner E12 to an E-box
in the Myog promoter (Fig. 5B). Similar repression was seen
when an E-box in the MCK promoter was used as a probe (Fig.
5C and SI Fig. 10B). GST pulldown (Fig. 5D) and coimmuno-
precipitation (Fig. 5E) assays revealed direct contact between
MyoD and Myocd. Taken together, these results suggest that the
physical interaction between MyoD and Myocd impacts nega-
tively on MEF2–MyoD functional association and optimal
MyoD DNA binding.
Myocd-Mediated Repression of Myog Requires Histone Deacetylase 5
(HDAC5). Because Myocd’s activity is subject to regulation by
chromatin-remodeling factors, such as HDAC5 (18), we tested
whether repression might proceed in an HDAC-dependent
manner. Class II HDACs were equivalent to Myocd in repressing
the Myog promoter (Fig. 6A). Moreover, Myocd’s repression
could be reversed with the HDAC inhibitor trichostatin A (Fig.
6B), and cotransfection of HDAC5 with Myocd resulted in a
stepwise decrease in MyoD-stimulated Myog promoter activity
(Fig. 6C). To directly evaluate the role of HDAC5, we trans-
duced C2C12 cells stably expressing Myocd with an adenovirus
carrying antisense HDAC5. As shown in Fig. 6D, HDAC5
antisense caused a decrease in HDAC5 mRNA and protein and
an increase in the Myog protein.
Discussion
The results of this study reveal Myocd to be an early marker of
skeletal muscle lineages and a negative regulator of the tran-
scriptional program for skeletal muscle differentiation. Skeletal
myoblasts overexpressing Myocd either transiently or stably are
refractory to terminal differentiation and acquire an SMC-like
phenotype. The ability of Myocd to block skeletal muscle
differentiation can be attributed, at least in part, to its transcrip-
tional repression of Myog, an essential activator of skeletal
muscle gene expression. This transcriptional repression appears
to involve multiple mechanisms involving the recruitment of
HDAC5, as well as an obstruction to both MEF2–MyoD func-
tional association and MyoD DNA binding to the Myog pro-
moter. The transient expression of Myocd within the somitic
compartment of the mouse embryo provides a biological context
where Myocd may function in the transdifferentiation of skeletal
myoblasts to a SMC-like lineage. Our results support the concept
of Myocd acting as a bifunctional switch for smooth versus
skeletal muscle differentiation.
Repression of Skeletal Muscle Differentiation by Myocd. Myocd was
first reported to be a strong transactivator through physical
association with SRF bound to CArG elements in the regu-
latory regions of cardiac- and SMC-restricted genes (8, 9).
Here we report that Myocd displays repressor activity over the
Myog promoter even when the conserved CArG element is
mutated or deleted, indicating that transrepression is inde-
pendent of CArG-SRF. This finding is further supported by
our Myocd-mapping studies demonstrating that the repressive
activity of Myocd did not require the basic domain of Myocd,
which mediates SRF binding. Thus, Myocd displays a broader
role in regulating gene expression than previously thought.
Consistent with this concept, a microarray screen in human
skeletal myoblasts transduced with Myocd revealed repression
of many genes, including Myog (19). Moreover, Myocd inhibits
cell growth (20) and malignant transformation (21), although
it is unclear whether these effects are due to repression of
growth-regulatory genes.
The mechanisms for Myocd’s transrepression of the Myog
promoter are complex. Myocd interacts with positive (p300)
and negative (HDAC5) coregulators of chromatin remodeling
to effect changes in SMC gene expression (18). Here we show
that the HDAC5 interacting domain of Myocd (poly Q) is
partly required for transrepression. Further, antisense-
HDAC5 rescues the suppression of Myog in cells stably
transfected with Myocd. Interestingly, repression cannot be
rescued with p300 (data not shown), which physically binds to
the TAD of Myocd (18) and is a crucial coactivator of
MyoD-dependent gene expression (22). This outcome implies
that repression is not the result of Myocd binding limiting
Fig. 6. HDAC5 mediates Myocd’s repression of the Myog promoter. (A) C2C12
myoblasts cotransfected with the 660 Myog-Luciferase reporter (Myog-Luc)
in the absence (Vector) or presence of Myocd or various Class II HDACs.
Luciferase activity is expressed as a percentage of the vector control (set to
100). (B) 10T1/2 cells cotransfected with Myog-Luc and MEF2C-VP16  Myocd
in the absence or presence of 200 nM TSA. Luciferase activity is expressed as in
A. (C) C2C12 myoblasts cotransfected with Myog-Luc and MyoD-E47  MEF2C
with 50 ng Myocd and varying amounts (ng) of HDAC5 as indicated. (D) C2C12
cells stably transfected with Myocd transduced with either control or anti-
sense HDAC5 adenovirus and processed 72 h later for RT-PCR (Top) or Western
blotting (Middle) of HDAC5. (Bottom) Western blot of endogenous Myog
protein. All experiments shown are representative of at least two indepen-
dent experiments.














amounts of p300. Because the TAD of Myocd is essential for
its transrepression activity, this domain may interact with
another protein to mediate transcriptional repression. One
potential candidate is MyoD, which we show by GST pulldown
and coimmunoprecipitation assays to physically associate with
Myocd. MyoD–Myocd complexes likely account for attenuated
MEF2–MyoD functional association and reduced MyoD bind-
ing to E-boxes in the Myog promoter.
Skeletal muscle differentiation and the MRFs are consid-
ered to be dominant over other cell types, including cardiac
and smooth muscle (2, 23). Importantly, the apparent domi-
nance of the skeletal muscle program over SMCs only has been
shown in vitro, where levels of Myocd are low. We suggest that
the stoichiometry of Myocd is critical in maintaining SMC
differentiation. When Myocd levels are low, SMCs lose their
differentiated phenotype and may take on other cell fates.
However, when Myocd levels are elevated, cells are more likely
to adopt an SMC fate. Interestingly, we have shown MyoD
to have no effect on Myocd-dependent transactivation of
SMC-restricted promoters, suggesting that Myocd can override
the actions of MRFs and the skeletal muscle program of
differentiation.
Myocd as an Early Marker of the Skeletal Muscle Lineage. Retro-
spective clonal analysis in mice has shown some embryonic aortic
SMCs to arise from the dermamyotome of somites, thereby
providing evidence for the existence of a common progenitor for
smooth and skeletal muscle (24). Recently, quail-chick trans-
plantation studies also found the sclerotome compartment of the
somite to be a source of aortic SMCs (25). We detected lacZ
expression directed by Myocd-Cre in both the dermamyotome
and the sclerotome. Regardless of the somitic origins of aortic
SMCs, the expression of Myocd-Cre suggests that Myocd is
expressed in somitic progenitor cells that may give rise to aortic
SMCs. Therefore, it is possible that a subpopulation of Myocd-
expressing cells within the somites is prevented from differen-
tiating into myotubes or other cell types (e.g., bone), thus
allowing these cells to migrate to the dorsal aorta and differen-
tiate into vascular smooth muscle. Because Myocd expression is
not detected in the skeletal muscle lineage beyond E9.0 (8), we
propose that Myocd is required only transiently in a common
progenitor of skeletal and smooth muscle lineages, and that its
subsequent repression is required for skeletal muscle
development.
There are several instances during development where SMCs
transdifferentiate into skeletal muscle (26–28). We hypothesize
that a critical prerequisite for SMC–skeletal muscle transdiffer-
entiation is the silencing of Myocd expression. In support of this
premise, cultured SMCs with a propensity to transdifferentiate
into skeletal muscle (14) display low-level expression of Myocd
(20). It will be interesting to investigate whether the types of
repressive mechanisms observed here also are operative in
settings of SMC phenotypic modulation, as occurs during patho-
logical vascular remodeling in vivo. Finally, VEGF can promote
the transdifferentiation of skeletal myoblasts or muscle-derived
stem cells into functional SMCs (29). Because VEGF is under
study in a variety of angiogenesis clinical trials, it may be prudent
to evaluate skeletal muscle function in patients undergoing this
type of therapy.
In summary, we identified a new function of Myocd related to
the transcriptional repression of Myog and the respecification of
skeletal myoblasts to a SMC-like lineage. We propose that
Myocd functions as a bifunctional molecular switch for muscle
differentiation, advancing SMC differentiation while repressing
the skeletal muscle differentiation program. These studies have
important implications for understanding the molecular under-
pinnings associated with transdifferentiation of skeletal muscle
and smooth muscle during development and the derivation of
these cell types from stem cells.
Materials and Methods
PCR primers and antibodies are listed in SI Tables 1 and 2.
Generation of Myocd-Cre Knockin Mice. The Myocd-Cre knockin
mouse was created with standard methods detailed in SI Mate-
rials and Methods.
Cell Culture. Cells were grown without antibiotics at 37°C in 10%
FBS. C2C12 myoblasts were induced to differentiate with 2.5%
horse serum for 72 h. Transfections, transductions, and deriva-
tion of stable cell lines were done with standard procedures
described in SI Materials and Methods.
Expression Analyses. RT-PCR, Western blotting, and immunoflu-
orescence microscopy were done on various cell types with
standard methods as detailed in SI Materials and Methods.
DNA–Protein and Protein–Protein Interaction Assays. Gel-shift, GST
pulldown, and coimmunoprecipitation assays were done with
established techniques as detailed in SI Materials and Methods.
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